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Background: The United States Institute of Medicine (IOM) published reports in 1999 and 
2011 identifying drug use as a priority area for sexual minority health research, specifically 
focused on mechanisms contributing to drug use disparities and the development of tailored 
interventions. Limited research has prioritized sexual minority women (SMW) with the 
majority of substance use research among sexual minorities focused on adolescents and men 
who have sex with men. This scoping review will characterize the research literature related 
to illicit drug use and prescription drug misuse among SMW and sub-groups within the SMW 
population. Through this, we will identify: (1) specific substances used; (2) patterns of 
substance use; (3) risk and protective factors; (4) prevention interventions; and (5) drug 
treatment programs specific to SMW. 
 
Methods/Design: This review will include studies with empirical data of illicit or prescription 
drug misuse among sexual minority women. Peer-reviewed quantitative research conducted 
in the United States and published in English from 2011-Present will be included. We will 
search Medline, PsycINFO, and Web of Science databases for relevant articles. Two 
independent reviewers will screen abstracts and relevant full-text studies for eligibility. Data 
will be extracted from eligible articles and results will be presented in narrative and tabular 
form as appropriate. 
 
Discussion: This work will identify gaps of knowledge in the research pertaining to illicit or 
prescription drug misuse among sexual minority women since the 2011 US IOM report. As a 
result of this work, we will propose directions for future research to address identified gaps. 
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1.  Background 
Substance use continues to be a prominent public health concern in the United States (US) 
(Centers for Disease Control and Prevention, 2019; Substance Abuse and Mental Health 
Services Administration, 2018). Research shows that marginalized and stigmatized 
populations, such as sexual minorities, are disproportionately at higher risk for using licit and 
illicit substances (Johns et al., 2018; Mennis & Stahler, 2016). Sexual minorities comprise 
individuals who identify their sexual orientation as non-heterosexual (e.g., lesbian, gay, 
bisexual, or queer), report same-sex sexual behavior, or same-sex sexual attraction. Female, 
male, and transgender sexual minorities experience unique stressors and contexts based on 
their gender and sexuality that impact their physical and mental health (Schuler et al., 2019). 
These stressors are often the result of stigma and discrimination related to being a sexual 
minority (Goldbach et al., 2014). Minority stress can be the source of social and emotional 
distress resulting in substance use as a coping mechanism (Goldbach et al., 2014; Lehavot & 
Simoni, 2011). The adverse outcomes of minority stress are augmented by other socio-
ecological factors, including higher rates of unemployment and lower levels of health 
insurance coverage among sexual minorities (Charlton et al., 2018).  
To date, sexual minority men have been the predominant focus of sexual minority 
research, particularly in the area of substance use (Coulter et al., 2014; Heath et al., 2012; 
Melendez-Torres & Bourne, 2016; Vosburgh et al., 2012). With a higher proportion of 
women (5.1%) identifying as a sexual minority compared to men (3.9%) and more women 
(12.6%) reporting sexual acts with same-sex partners than men (2.8%), the dearth of research 
and understanding of substance use among sexual minority women (SMW) is concerning 
(Copen et al., 2016; Newport, 2018).  
In 1999, the US Institute of Medicine (IOM) Committee on Lesbian, Gay, Bisexual, and 
Transgender Health Issues published a report on the health of lesbians in the US, finding that 
substance use was a pressing health issue for SMW and identifying major gaps in existing 
knowledge and research (Solarz, 1999). While this report noted substantial limitations in the 
research literature, preliminary evidence suggested that lesbian women reported higher use of 
cocaine, inhalants, and marijuana compared to heterosexual women (Solarz, 1999). 
Ultimately, the 1999 report called for more extensive research on drug use patterns and risks 
among SMW to further understand the patterns and context of problematic use within this 
often-overlooked population.  
In 2011, the IOM published an updated report on the health of sexual and gender 
minorities and still identified substance use as a particularly critical and understudied issue 
(Graham et al., 2011). The 2011 report found that there were distinct differences in subgroups 
of sexual minorities’ substance use and abuse (Graham et al., 2011). More specifically, 
adolescent bisexual girls, when compared to both heterosexual and other sexual minority 
boys and girls, were the most likely to have tried marijuana and other illicit drugs (Graham et 
al., 2011). Similar findings were reported among adults, with women who have sex with 
women more likely to report injection drug use compared to women who only have sex with 
men (Graham et al., 2011). Overall, substance use disparities by sexual minority status were 
also greater for SMW compared to sexual minority men (Graham et al., 2011). Although the 
findings of this thorough review of existing research suggested heightened sexuality 
differences in use for women, the report had only a limited discussion of other risk factors or 
determinants of drug use disparities in SMW.   
The objective of this scoping review is to build upon previous efforts to understand the 
current state of research on drug use behaviors among SMW by exploring research on illicit 
drug use conducted in the US since the 2011 IOM report. Specifically, we will assess the 
 




current knowledge regarding drug use for SMW. We will identify gaps in the existing 
literature and propose new directions for research and public health efforts moving forward. 
We conducted a preliminary search of databases [PubMed (National Library of Medicine), 
APA PsycInfo, Prospero, and Joanna Briggs Institute Database of Systematic Reviews and 
Implementation Reports] to ensure this work is not duplicative of previously published 
reviews or protocols. Despite the two IOM reports highlighting drug use disparities among 
SMW, we discovered that a limited understanding of the risk and protective factors, and 
existing prevention and intervention efforts for drug use among SMW still remains. Research 
analyzing substance use among sexual minorities has traditionally focused on disparities in 
alcohol and tobacco use with less emphasis on illicit drugs and prescription drug misuse 
(Hughes et al., 2020; Talley et al., 2016). This was reflected in a recent scoping review of 
substance use among SMW globally (Hughes et al., 2020). The principle findings of this 
scoping review focused on alcohol use with limited mention of specific other drug use 
(Hughes et al., 2020). As a result, we still have a limited understanding of the specific illicit 
drug use and prescription drug misuse patterns, social determinants, or interventions among 
SMW in the US (Meyer et al., 2019).  
We believe that a scoping review of drug use among SMW is warranted, especially given 
the duration of time since the last major review of the literature. This scoping review will 
characterize the research literature related to drug use and prescription drug misuse among 
SMW and sub-groups within the SMW population. Through this, we will identify: (1) 
specific substances used; (2) patterns of substance use; (3) risk and protective factors; (4) 
prevention interventions; and (5) drug treatment programs specific to SMW. Only those 
studies conducted with SMW living in the United States and territories and published since 
2011 will be included in this scoping review. 
 
2.  Methods/Design 
The JBI Manual for Evidence Synthesis (Peters et al., 2017) was used to guide the 
development of this scoping review. Study execution was assessed using the appropriate 
criteria from the AMSTAR 2.0 checklist (Faggion, 2015). The PRISMA Extension for 
Scoping Reviews (PRISMA-ScR) (Tricco et al., 2018) was followed to write this review.  
 
2.1  Inclusion criteria 
This scoping review aims to understand the progress of the field of drug use research 
among SMW. The inclusion criteria presented in Table 1 are reflective of the key attributes of 
studies related to our primary objective to determine the state of research almost 10 years 
after the 2011 IOM report. Each of the inclusion criteria are described in detail below. 
 
Table 1.  Inclusion criteria. 
 
Category Criteria 
Types of participants Cisgender sexual minority females 
Outcomes Illicit drug use or prescription drug misuse  
Context United States and US territories 
Types of Sources Quantitative, empirical peer-reviewed journal articles published in 









2.1.1  Types of participants 
This review will consider studies that explicitly identify SMW participants in the United 
States. For the purposes of this review, SMW is defined as cisgender women who either 
identify as a sexual minority (i.e., lesbian, bisexual, queer, etc.) and/or report same-sex sexual 
behavior and/or attraction. We will be inclusive with regard to the inclusion of SMW, 
including sexual orientation, behavior, and attraction as indicators of sexual minority status 
because individuals from disadvantaged and/or racial/ethnic minority communities that 
engage in same-sex behavior are less likely to identify as a sexual minority and individuals 
who engage in same-sex sexual behavior, regardless of sexual identity, often experience 
similar discrimination and stressors as those who identify as gay, lesbian, bisexual, or queer 
(Copen et al., 2016; Lindley et al., 2012; McCabe et al., 2005; Teasdale & Bradley-Engen, 
2010). All age and race/ethnicity groups will be included in this review. 
 This scoping review will exclude articles that exclusively focus on gender minorities (i.e., 
transgender or nonbinary individuals). Because gender minorities have unique experiences 
from cisgender women that may influence their substance use behaviors, these factors are 
beyond the scope of this review (James et al., 2016). A separate review should be conducted 
that takes into consideration these experiences and the unique social and political contexts 
surrounding gender minorities and substance use.  
 
2.1.2  Outcomes 
This review will include studies that examine illicit drug use or prescription drug misuse 
as the outcome variable. As such, studies examining drug use patterns, correlates, risk and 
protective factors, and interventions and treatment programs for drug use specifically among 
SMW will be included. Studies will be included if they provide empirical quantitative data 
regarding drug use outcomes in this population.  
For the purposes of this review, illicit drug use includes the consumption by any method 
(e.g., injecting, inhaling, smoking) of illegal substances (e.g., cocaine, heroin, inhalants, 
methamphetamines, hallucinogens), regardless of dosage or frequency. As 
marijuana/cannabis remains a prohibited substance in many U.S. states as well as at the 
federal level as of the time of this review, it will be included as an illicit substance. However, 
cannabis used appropriately for medicinal purposes will be excluded. Prescription drug 
misuse will include the consumption of any prescription drug (e.g., opioids, benzodiazepines, 
stimulants, medicinal cannabis) that is used either without a prescription from a healthcare 
provider or misused from the way it was originally prescribed. Studies exclusively focused on 
alcohol or tobacco use will be excluded. Measures of general substance use which do not 
identify specific drugs will be included unless alcohol and/or tobacco are included in the 
measure.  
 
2.1.3  Context 
This review will consider studies that include results from individuals in the United States 
or the US territories (American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and 
the U.S. Virgin Islands). This review is limited to the United States due to specific and 
significant historical and policy issues surrounding both sexual minority populations and 










2.1.4  Types of sources 
This scoping review will consider articles in the peer-reviewed scientific literature. Studies 
presenting quantitative empirical and original data will be included. Articles presenting only 
qualitative data, literature review articles, research or intervention protocols, commentaries, 
opinion articles, or other types of publications that do not present empirical, quantitative 
results will be excluded. Clinical and individual case studies will also be excluded. 
This review will be limited to articles published in English from 2011 to the present. As 
described previously, the year 2011 was selected due to the publication of IOM report on 
sexual and gender minority health, which presented a thorough examination of substance use 
among SMW through 2010 (Graham et al., 2011) . As such, this review aims to build on the 
IOM’s previous work and examine the state of drug use research among SMW in the time 
following the release of this report.  
 
2.2  Search strategy 
The databases to be searched include Medline (PubMed), PsycINFO, and Web of Science. 
The search will be limited to peer-reviewed journals and articles published from 2011-
Present. After conducting a database search for relevant literature and identifying over 1800 
peer-reviewed studies, it was determined that gray literature will be excluded considering the 
number of studies included in the analysis.  
The search strategy will aim to locate published, peer-reviewed articles in electronic 
databases. An initial limited search strategy was developed and pilot tested by a health 
research librarian on Medline (PubMed) to identify articles on the topic. The text words 
contained in the titles and abstracts of relevant articles, the index terms used to describe the 
articles, and medical subject headings (e.g., MeSH terms) were used to develop a full search 
strategy (see Appendix I). The basic search strategy includes the concepts SMW and illicit 
and prescription drugs. Filters for English language, human subjects, and the United States 
were applied. The full search strategy, including all identified keywords and index terms, will 
be adapted for each included information source (Medline, PyschINFO, and Web of Science). 
  
2.3  Study selection 
Following the search, all identified records will be collated and uploaded into DistillerSR 
(Evidence Partners, Ottawa, Canada) and duplicates will be removed. Titles and abstracts will 
then be screened independently by two reviewers for assessment against the inclusion 
criteria. Potentially relevant papers will be retrieved in full and their citation details imported 
into DistillerSR. The full text of selected citations will then be assessed in detail against the 
inclusion criteria by two independent reviewers to confirm eligibility. Reasons for exclusion 
of full-text articles will be documented and reported in the scoping review. Any discrepancies 
that arise between the reviewers at each stage of the selection process will be resolved 
through discussion or by consulting a third reviewer. The results of the search and study 
selection process will be reported in full in the final scoping review and presented in a flow 
diagram as described by the Preferred Reporting Items for Systematic Reviews and Meta-
analyses Extension for Scoping Reviews (PRISMA-ScR) (Tricco et al., 2018). 
 
2.4  Data extraction 
Data will be extracted from papers included in the scoping review using a data extraction 
tool developed by the reviewers. A draft extraction tool is provided in Appendix II. The draft 
data extraction tool will be modified and revised as necessary during this process. 
 




Modifications will be detailed in the full scoping review. Any disagreements that arise 
between the reviewers will be resolved through discussion or by consulting a third reviewer.  
Two primary categories of studies will be created: 1) observational studies (research 
examining drug use patterns, risk/protective factors, and/or health and social factors 
associated with drug use), and 2) intervention or program evaluation studies in which drug 
use is the outcome. Within each of these two categories, the data extracted, as appropriate, 
will include specific details about the sample size and characteristics (e.g., age, 
race/ethnicity), study focus and objectives, types of drugs examined and measurement of use, 
measurement of SMW, and key findings. 
 
3.  Presentation of results 
This scoping review aims to present an overview of existing research on illicit and 
prescription drug use among SMW in the United States since the 2011 IOM report (Graham 
et al., 2011). The extracted data will be presented in a narrative form, accompanied by tables 
and figures as appropriate, in a manner that aligns with this scoping review’s objective. Data 
will be presented in two tables, one for each category of studies (observational studies and 
intervention studies). Within these tables, findings will be stratified by drug examined. 
Additionally, PRISMA-ScR will be used to guide the presentation of the results to ensure 
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Appendix I.  Search strategy for PubMed.  
Search conducted on March 5, 2019 
Number Search Terms Items found 
#14 Limit #13 to 2011-Present 994 
#13 Search (#11 AND #12) 1854 
#12 
Search ((Alabama[TIAB] OR Alaska[TIAB] OR Arizona[TIAB] OR 
Arkansas[TIAB] OR California[TIAB] OR Colorado[TIAB] OR 
Connecticut[TIAB] OR Delaware[TIAB] OR District of 
Columbia[TIAB] OR "Washington, DC"[TIAB] OR Florida[TIAB] OR 
Georgia[TIAB] OR Hawaii[TIAB] OR Idaho[TIAB] OR Illinois[TIAB] 
OR Indiana[TIAB] OR Iowa[TIAB] OR Kansas[TIAB] OR 
Kentucky[TIAB] OR Louisiana[TIAB] OR Maine[TIAB] OR 
Maryland[TIAB] OR Massachusetts[TIAB] OR Michigan[TIAB] OR 
Minnesota[TIAB] OR Mississippi[TIAB] OR Missouri[TIAB] OR 
Montana[TIAB] OR Nebraska[TIAB] OR Nevada[TIAB] OR "New 
Hampshire"[TIAB] OR "New Jersey"[TIAB] OR "New Mexico"[TIAB] 
OR "New York"[TIAB] OR "North Carolina"[TIAB] OR "North 
Dakota"[TIAB] OR Ohio[TIAB] OR Oklahoma[TIAB] OR 
Oregon[TIAB] OR Pennsylvania[TIAB] OR "Rhode Island"[TIAB] OR 
"South Carolina"[TIAB] OR "South Dakota"[TIAB] OR 
Tennessee[TIAB] OR Texas[TIAB] OR Utah[TIAB] OR 
Vermont[TIAB] OR Virginia[TIAB] OR Washington[TIAB] OR "West 
Virginia"[TIAB] OR Wisconsin[TIAB] OR Wyoming[TIAB] OR 
United States[TIAB] OR U.S.[tiab] OR USA[tiab] OR U.S.A.[tiab])) 
OR (("United States"[MeSH] OR United States[PL] OR United 
States[GR])) OR ((United States[AD] OR USA[AD] OR U.S.A.[AD] 
OR U.S.[AD] OR Alabama[AD] OR Alaska[AD] OR Arizona[AD] OR 
Arkansas[AD] OR California[AD] OR Colorado[AD] OR 
Connecticut[AD] OR Delaware[AD] OR District of Columbia[AD] OR 
"Washington, DC"[AD] OR Florida[AD] OR Georgia[AD] OR 
Hawaii[AD] OR Idaho[AD] OR Illinois[AD] OR Indiana[AD] OR 
Iowa[AD] OR Kansas[AD] OR Kentucky[AD] OR Louisiana[AD] OR 
Maine[AD] OR Maryland[AD] OR Massachusetts[AD] OR 
Michigan[AD] OR Minnesota[AD] OR Mississippi[AD] OR 
Missouri[AD] OR Montana[AD] OR Nebraska[AD] OR Nevada[AD] 
OR "New Hampshire"[AD] OR "New Jersey"[AD] OR "New 
Mexico"[AD] OR "New York"[AD] OR "North Carolina"[AD] OR 
"North Dakota"[AD] OR Ohio[AD] OR Oklahoma[AD] OR 
Oregon[AD] OR Pennsylvania[AD] OR "Rhode Island"[AD] OR "South 
Carolina"[AD] OR "South Dakota"[AD] OR Tennessee[AD] OR 
Texas[AD] OR Utah[AD] OR Vermont[AD] OR Virginia[AD] OR 
Washington[AD] OR "West Virginia"[AD] OR Wisconsin[AD] OR 
Wyoming[AD] AND (English[lang]))) 14,323,987 
#11 Search (#9 NOT #10) 2,723 
 




#10 Search (animals[mh] NOT (animals[mh] AND humans[mh])) 4,553,519 
#9 Search (#7 AND #8) 2,728 
#8 Search English[Language] 24,781,459 
#7 Search (#5 AND #6) 3,091 
#6 
sh:noexp] OR Substance Withdrawal Syndrome[mh] OR addict*[tiab] 
OR amphetamine*[tiab] OR cannabis[tiab] OR Chetiab] OR 
cocaine[tiab] OR drug abuse*[tiab] OR drug misuse* OR drug 
use*[tiab] OR heroin[tiab] OR illicit drug*[tiab] OR marijuana[tiab] OR 
narcotic*[tiab] OR opiate*[tiab] OR opioid*[tiab] OR recreational 
drug*[tiab] OR Street drug*[tiab]) 381,739 
#5 Search (#1 OR #4) 19,469 
#4 Search (#2 AND #3) 17,341 
#3 
Search (Female[Mesh] OR Female*[tiab] OR Woman*[tiab] OR 
Women*[tiab]) 8,497,304 
#2 
Search ((Bisexuality[MeSH Terms] OR Homosexuality[mh:noexp] OR 
Sexual and Gender Minorities[mh:noexp] OR bicurious[tiab] OR 
bisexual[tiab] OR bisexuality[tiab] OR bisexuals[tiab] OR gay[tiab] OR 
gays[tiab] OR Gender minorit*[tiab] OR gender queer[tiab] OR 
genderqueer[tiab] OR GLB[tiab] OR GLBQ[tiab] OR GLBs[tiab] OR 
GLBT[tiab] OR GLBTQ[tiab] OR heteroflexible[tiab] OR homo 
sex*[tiab] OR homosexual[tiab] OR homosexualities[tiab] OR 
homosexuality[tiab] OR homosexuals[tiab] OR LGB[tiab] OR 
LGBQ[tiab] OR LGBS[tiab] OR LGBT[tiab] OR queer[tiab] OR same 
gender loving[tiab] OR same sex attracted[tiab] OR Same sex 
behavior[tiab] OR same sex couple*[tiab] OR Same sex experience[tiab] 
OR same sex relations[tiab] OR Same sex sexualit*[tiab] OR sexual 
identity[tiab] OR sexual minorities[tiab] OR sexual minority[tiab] OR 
sexual orientation[tiab] OR sexual preference[tiab]) NOT (laparoscopic 
gastric bypass[tiab] OR gay[au])) 34,704 
#1 
Search (Homosexuality, female[MeSH Terms] OR lesbian[tiab] OR 
lesbianism[tiab] OR lesbians[tiab] OR lesbigay[tiab] OR women loving 
women[tiab] OR women who have sex with women[tiab] OR 
WSW[tiab] OR WSWM[tiab]) 7,011 
 




Appendix II.  Data extraction instrument. 
Article and Study Characteristics: 
Author(s)  
Year of Publication  
Study Primary Purpose/Objective:  
Study Design (e.g., Cohort, Cross-sectional):  
Theoretical Framework:  
Location of Study:  
Recruitment Setting (e.g., hospital, drug treatment):  
Sampling Design (e.g., random, convenience):  
Data Collection Methods:  
SMW Sample Characteristics: 
Sample Size – Total:  
Sample Size - Sexual Minority Women:  
Sample Age Range:  
Age Range of Sexual Minority Women (if 
presented): 
 
Sample Race/Ethnicity Composition:  
Race/Ethnicity Composition of Sexual Minority 
Women (if presented): 
 
Inclusion/Exclusion Criteria:  
Measurement/Analysis:  
Identification and measurement of sexual minority 
status (identity, behavior, etc.): 
 
Drugs Examined:  
 




Measurement of Drug Use:  
Primary Outcome of Study and Measurement of 
Variable: 
 
Primary Independent Variable and Measurement of 
Variable: 
 
Covariates Examined:  
Intervention or Drug Treatment Description (if 
applicable): 
 
Qualifying drug outcome(s) among SMW:  
 
 
